– Interview with George Calin, M.D., Ph.D., Associate Professor, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center

PodcastsResourcesCancersCellular, Molecular and Developmental BiologyGenetic variantsGeneticsMedicine, Diagnosis, and TherapeuticsmiRNA (Nucleic acids)Molecular biologyMutationNucleic acidsOMICSRNASystemic conditionsTherapeutics
Previous articleEMD and Merck Serono to Fork Out $50M for New Research Center in Massachusetts
Next articleArtes Biotechnology Produces Virus-Like Particles for Select Vaccines from a Yeast-Based System